Cutaneous T-cell Lymphoma

P1, N=42, Not yet recruiting, University of Pennsylvania | Trial completion date: Apr 2043 --> Jul 2051 | Initiation date: Apr 2026 --> Jul 2026 | Trial primary completion date: Apr 2043 --> Jul 2051

P2, N=23, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Apr 2027 --> Dec 2027 | Trial primary completion date: Apr 2026 --> Dec 2026

Along with signs of an insufficient coping response to hypoxia, these stromal reactions might be critical contributors to spontaneous lesion regression in LyP. Taken together, this study reveals mediators associated with the self-limited behavior of LyP lesions, which might be relevant for future immunomodulatory treatment strategies in CTCL.

Although elevated dermal GATA3 expression may support the diagnosis of MF in some cases, its substantial overlap with BID and low sensitivity limit its utility as a reliable standalone diagnostic marker for early-stage MF. GATA3 can be incorporated into broader immunohistochemical panels alongside more specific markers to improve diagnostic accuracy.

This case highlights the diagnostic gray zone between clonal reactive lymphoid proliferations and PCSM-TCLPD in very young children, an age group in which such presentations are exceedingly rare, and emphasizes the importance of clinicopathologic correlation, multidisciplinary evaluation, and cautious management. It also raises awareness that these entities may exist along a biological spectrum rather than representing entirely distinct processes.

This case emphasizes a diagnostic challenge in distinguishing round cell tumors in cats and the critical role of immunohistochemistry in achieving an accurate diagnosis. The tumor also showed aggressive clinical behavior, including suspected distant metastasis, and may have arisen in association with chronic inflammation at a prior injection site.

These markers showed positive correlations, and elevated expression, especially of B7-H3 and CD163, was associated with shorter disease-free survival in univariate analysis. The higher expression of CD47, CD163, and B7-H3 in early-stage MF compared with LPP suggests that these markers may contribute to the differential diagnosis and could represent potential therapeutic targets; however, their independent prognostic value requires confirmation in larger studies.

P=N/A, N=15, Enrolling by invitation, Northwestern University | Not yet recruiting --> Enrolling by invitation | Trial completion date: Nov 2025 --> Dec 2027 | Trial primary completion date: Nov 2025 --> Jun 2027

P1, N=25, Recruiting, Northwestern University | Trial completion date: Feb 2026 --> Dec 2027 | Trial primary completion date: Aug 2025 --> Jun 2027

P1, N=30, Not yet recruiting, Northwestern University | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2028

This study demonstrates that SS is distinguished from PCAECTCL not by increased mutational burden but by distinct pathway-level architectures, particularly involving epigenetic regulation, immune signaling, and transcriptional control. These findings generate biologically grounded, testable hypotheses for subtype-specific therapeutic targeting and underscore the value of conversational AI as a scalable framework for accelerating discovery in translational cancer genomics.

P2, N=170, Completed, Innate Pharma | Active, not recruiting --> Completed | Trial primary completion date: Oct 2023 --> Jan 2026